Genetic variants of pulmonary SP-D predict disease outcome of COPD in a Chinese population

Respirology

Volumn 20, Issue 2, 2015, Pages 296-303

  Ou, Chih Ying ^a   Chen, Chiung Zuei ^a   Hsiue, Tzuen Ren ^a   Lin, Sheng Hsiang ^b   Wang, Jiu Yao ^c,d  

^a Division of Chest Medicine   (Taiwan)

^b Institute of Clinical Medicine   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

chronic obstructive pulmonary disease; haplotype; polymorphism; surfactant protein D

Indexed keywords

BRONCHODILATING AGENT; SURFACTANT PROTEIN D; BIOLOGICAL MARKER;

AGED; AIRWAY OBSTRUCTION; ARTICLE; CHINESE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION; HAPLOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CASE CONTROL STUDY; CHINA; DISEASE COURSE; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; CHINA; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; SURVIVAL RATE;

EID: 84921455184     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12427     Document Type: Article

References (30)

1. Office of Information Services, Executive Yuan. Public Health in 2011 ROC Year Book. Executive Yuan, Taiwan, 2011. [Accessed 30 Aug 2013.] Available from URL: http://www.ey.gov.tw/en/cp.aspx?n=CBDA2319F19402AE
2. World Health Organization. The World Health Report 2002. Burden of COPD. World Health Organization, Geneva, 2002.
3. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J,. Developing COPD: a 25-year follow-up study of the general population. Thorax 2006; 61: 935-939.
4. Sandford AJ, Silverman EK,. Chronic obstructive pulmonary disease. 1: susceptibility factors for COPD the genotype-environment interaction. Thorax 2002; 57: 736-741.
5. Molfino NA,. Genetics of COPD. Chest 2004; 125: 1929-1940.
6. Kishore U, Greenhough TJ, Waters P, Shrive AK, Ghai R, Kamran MF, Bernal AL, Reid KB, Madan T, Chakraborty T,. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol. Immunol. 2006; 43: 1293-1315.
7. Groves AM, Gow AJ, Massa CB, Laskin JD, Laskin DL,. Prolonged injury and altered lung function after ozone inhalation in mice with chronic lung inflammation. Am. J. Respir. Cell Mol. Biol. 2012; 47: 776-783.
8. Liu CF, Chen YL, Chang WT, Shieh CC, Yu CK, Reid KB, Wang JY,. Mite allergen induces nitric oxide production in alveolar macrophages via the CD14/TLR4 complex, and is inhibited by surfactant protein D. Clin. Exp. Allergy 2005; 35: 1615-1624.
9. Jäkel A, Clark H, Reid KB, Sim RB,. The human lung surfactant proteins A (SP-A) and D (SP-D) interact with apoptotic target cells by different binding mechanisms. Immunobiology 2010; 215: 551-558.
10. Yoshida M, Korfhagen TR, Whitsett JA,. Surfactant protein D regulates NF-B and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways. J. Immunol. 2001; 166: 7514-7519.
11. Knudsen L, Ochs M, Mackay R, Townsend P, Deb R, Muhlfeld C, Richter J, Gilbert F, Hawgood S, Reid K, et al. Truncated recombinant human SP-D attenuates emphysema and type II cell changes in SP-D deficient mice. Respir. Res. 2007; 8: 70-76.
12. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 185: 1065-1072.
13. Sin DD, Leung R, Gan WQ, Man SP,. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm. Med. 2007; 7: 13.
14. Foreman MG, Kong X, DeMeo DL, Pillai SG, Hersh CP, Bakke P, Gulsvik A, Lomas DA, Litonjua AA, Shapiro SD, et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2011; 44: 316-322.
15. Van Diemen CC, Postma DS, Aulchenko YS, Snijders PJ, Oostra BA, Van Duijn CM, Boezen HM,. Novel strategy to identify genetic risk factors for COPD severity: a genetic isolate. Eur. Respir. J. 2010; 35: 768-775.
16. Kim DK, Cho MH, Hersh CP, Lomas DA, Miller BE, Kong X, Bakke P, Gulsvik A, Agusti A, Wouters E, et al. Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186: 1238-1247.
17. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Revised 2011). Global Initiative for Chronic Obstructive Lung Disease (GOLD), Vancouver (WA), 2011. [Accessed 30 Aug 2013.] Available from URL: http://www.goldcopd.com
18. American Thoracic Society. Standardization of spirometry. Eur. Respir. J. 2005; 26: 319-338.
19. Sorensen GL, Husby S, Holmskov U,. Surfactant protein A and surfactant protein D variation in pulmonary disease. Immunobiology 2007; 212: 381-416.
20. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B. 1995; 57: 289-300.
21. Wang JY, Reid KBM,. The immunoregulatory roles of pulmonary surfactant protein A and D in allergic inflammation of asthma. Immunobiology 2007; 212: 417-425.
22. Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishioka Y, Sone S, Beers MF, Noble PW, Wright JR,. Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am. J. Respir. Crit. Care Med. 2012; 185: 525-536.
23. Hartl D, Griese M,. Surfactant protein D in human lung diseases. Eur. J. Clin. Invest. 2006; 36: 423-435.
24. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R,. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur. Respir. J. 2009; 34: 95-102.
25. Winkler C, Atochina-Vasserman EN, Holz O, Beers MF, Erpenbeck VJ, Krug N, Roepcke S, Lauer G, Elmlinger M, Hohlfeld JM,. Comprehensive characterization of pulmonary and serum surfactant protein D in COPD. Respir. Res. 2011; 11: 12-29.
26. Guo X, Lin HM, Lin Z, Montario M, Sansores R, Wang G, DiAngelo S, Pardo A, Selman M, Floros J,. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur. Respir. J. 2001; 18: 482-490.
27. Ishii T, Hagiwara K, Kamio K, Ikeda S, Arai T, Mieno MN, Kumasaka T, Muramatsu M, Sawabe M, Gemma A, et al. Involvement of surfactant protein D in emphysema revealed by genetic association study. Eur. J. Hum. Genet. 2012; 20: 230-235.
28. Matalon S, Shrestha K, Kirk M, Waldheuser S, McDonald B, Smith K, Gao Z, Belaaouaj A, Crouch EC,. Modification of surfactant protein D by reactive oxygen-nitrogen intermediates is accompanied by loss of aggregating activity, in vitro and in vivo. FASEB J. 2009; 23: 1415-1430.
29. Guo CJ, Atochina-Vasserman EN, Abramova E, Foley JP, Zaman A, Crouch E, Beers MF, Savani RC, Gow AJ,. S-nitrosylation of surfactant protein-D controls inflammatory function. PLoS Biol. 2008; 6: e266.
30. Atochina-Vasserman EN,. S-nitrosylation of surfactant protein D as a modulator of pulmonary inflammation. Biochim. Biophys. Acta 2012; 1820: 763-769.